Hypoactive Sexual Desire Disorder

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2020-07-31
Clinical Trial Update: Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study [Phase 3]
A Phase 3 clinical trial evaluating prasterone (DHEA) for hypoactive sexual desire disorder has been withdrawn.